Periodontal Resident University of Colorado, Anschutz Medical Campus Bonita, California, United States
Introduction: In dentistry placenta-derived products, have demonstrated efficacy in use as a membrane in regenerative and bone augmentation procedures. A novel growth factor serum consisting of micro-morselized, freeze-dried amnion membrane and plasma (AMS). Previous studies have demonstrated increased ossification in AMS-treated preosteoblasts, with the majority occurring within 7 days. The present study aims to characterize the early changes in preosteoblast gene expression following AMS treatment, over 72 hours.
Methods: MC3T3-E1 preosteoblast cells were cultured to confluence, with test group being treated with AMS 1:10, and sample RNA collected every 12 hours, for 72 hours. qRT-PCR was performed for BMP-2, PDGF-β, COL1A1, OSX and RunX2 and quantified using a GAPDH reference curve.
Results: qRT-PCR demonstrated a significantly reduced expression of RunX2, OSX, COL1A1 in AMS-treated preosteoblasts (p < 0.05), with a continued decrease in gene expression over 72 hours in both groups (p < 0.05). qRT-PCR for BMP-2 and PDGF-β did not amplify.
Conclusions: The present study does not support that AMS induces the expression of genes associated with osteogenesis or commitment of fibroblasts to the osteoblast phenotype, within 72 hours. Additional AMS studies are needed to confirm these findings; other placenta-derived biologics remain of high interest.
Lead Author’s Contributions to the Research Project: Created protocol and carried out experiment. Performed statistical analysis and wrote abstract.
